Bispecific Antibody Armed T Cells to Target Cancer Cells

2017 ◽  
pp. 117-126 ◽  
Author(s):  
Archana Thakur ◽  
Lawrence G. Lum ◽  
Sandeep Mittal
Keyword(s):  
T Cells ◽  
Cancer Cells ◽  
Bispecific Antibody ◽  
Target Cancer

scholarly journals CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth

Cancers ◽  
2017 ◽  
Vol 9 (12) ◽  
pp. 139 ◽  
Author(s):  
Vita Golubovskaya ◽  
Robert Berahovich ◽  
Hua Zhou ◽  
Shirley Xu ◽  
Hizkia Harto ◽  
...  
Keyword(s):  
T Cells ◽  
Tumor Growth ◽  
Cancer Cells ◽  
Pancreatic Tumor ◽  
Car T Cells ◽  
Car T ◽  
Target Cancer

scholarly journals Engineering light-controllable CAR T cells for cancer immunotherapy

2020 ◽  
Vol 6 (8) ◽  
pp. eaay9209 ◽  
Author(s):  
Ziliang Huang ◽  
Yiqian Wu ◽  
Molly E. Allen ◽  
Yijia Pan ◽  
Phillip Kyriakakis ◽  
...  
Keyword(s):  
T Cells ◽  
Cancer Cells ◽  
Cancer Immunotherapy ◽  
Tumor Antigens ◽  
Nuclear Translocation ◽  
Car T Cells ◽  
Car T ◽  
Target Cancer

T cells engineered to express chimeric antigen receptors (CARs) can recognize and engage with target cancer cells with redirected specificity for cancer immunotherapy. However, there is a lack of ideal CARs for solid tumor antigens, which may lead to severe adverse effects. Here, we developed a light-inducible nuclear translocation and dimerization (LINTAD) system for gene regulation to control CAR T activation. We first demonstrated light-controllable gene expression and functional modulation in human embryonic kidney 293T and Jurkat T cell lines. We then improved the LINTAD system to achieve optimal efficiency in primary human T cells. The results showed that pulsed light stimulations can activate LINTAD CAR T cells with strong cytotoxicity against target cancer cells, both in vitro and in vivo. Therefore, our LINTAD system can serve as an efficient tool to noninvasively control gene activation and activate inducible CAR T cells for precision cancer immunotherapy.

scholarly journals Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness

2021 ◽  
Vol 10 (1) ◽  
pp. 1930883
Author(s):  
Archana Thakur ◽  
Johnson Ung ◽  
Elyse N. Tomaszewski ◽  
Amy Schienschang ◽  
Timothy M. LaBrie ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
T Cells ◽  
Cancer Cells ◽  
Bispecific Antibody ◽  
Activated T Cells ◽  
Pancreatic Cancer Cells

mRNA-based CAR T-cells Manufactured by Miniaturized Two-step Electroporation Produce Selective Cytotoxicity Toward Target Cancer Cells

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Vidura Dhananjaya Jayasooriya ◽  
Beth Ringwelski ◽  
Glenn Dorsam ◽  
Dharmakeerthi Nawarathna
Keyword(s):  
T Cells ◽  
Side Effects ◽  
Cancer Cells ◽  
Chimeric Antigen Receptor ◽  
Viral Vector ◽  
Selective Cytotoxicity ◽  
Adverse Side Effects ◽  
Car T Cells ◽  
Car T ◽  
Target Cancer

There is a growing interest for viral vector-free chimeric antigen receptor (CAR) T-cells due to its ability to kill cancer cells without adverse side effects. A potential avenue for manufacturing...

scholarly journals Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0141669 ◽  
Author(s):  
Wibke Deisting ◽  
Tobias Raum ◽  
Peter Kufer ◽  
Patrick A. Baeuerle ◽  
Markus Münz
Keyword(s):  
T Cells ◽  
Cancer Cells ◽  
Immune Evasion ◽  
Bispecific Antibody

Abstract 2655: A novel Trop-2/CD3 trivalent bispecific antibody effectively redirects T cells to kill target human pancreatic and gastric cancer cells

2014 ◽  
Author(s):  
Diane L. Rossi ◽  
Thomas M. Cardillo ◽  
Edmund A. Rossi ◽  
Maria Zalath ◽  
David M. Goldenberg ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
T Cells ◽  
Cancer Cells ◽  
Bispecific Antibody ◽  
Gastric Cancer Cells

scholarly journals Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

mAbs ◽  
2018 ◽  
Author(s):  
Alessandro Satta ◽  
Delia Mezzanzanica ◽  
Francesco Caroli ◽  
Barbara Frigerio ◽  
Massimo Di Nicola ◽  
...  
Keyword(s):  
T Cells ◽  
Cancer Cells ◽  
Bispecific Antibody ◽  
Design Selection

scholarly journals Bone morphogenetic protein 7 promotes resistance to immunotherapy

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Maria Angelica Cortez ◽  
Fatemeh Masrorpour ◽  
Cristina Ivan ◽  
Jie Zhang ◽  
Ahmed I. Younes ◽  
...  
Keyword(s):  
T Cells ◽  
Immune System ◽  
Tumor Microenvironment ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Inflammatory Responses ◽  
Preclinical Models ◽  
Bone Morphogenetic Protein 7 ◽  
Morphogenetic Protein ◽  
Target Cancer

Abstract Immunotherapies revolutionized cancer treatment by harnessing the immune system to target cancer cells. However, most patients are resistant to immunotherapies and the mechanisms underlying this resistant is still poorly understood. Here, we report that overexpression of BMP7, a member of the TGFB superfamily, represents a mechanism for resistance to anti-PD1 therapy in preclinical models and in patients with disease progression while on immunotherapies. BMP7 secreted by tumor cells acts on macrophages and CD4+ T cells in the tumor microenvironment, inhibiting MAPK14 expression and impairing pro-inflammatory responses. Knockdown of BMP7 or its neutralization via follistatin in combination with anti-PD1 re-sensitizes resistant tumors to immunotherapies. Thus, we identify the BMP7 signaling pathway as a potential immunotherapeutic target in cancer.

Sign in / Sign up

Export Citation Format

Share Document